Startups
Cellestial Health
Cambridge neuroscience biotechnology spinout developing small-molecule medicines that protect astrocyte networks in the brain. Its preclinical pipeline seeks to slow Parkinson’s disease progression and address both motor and non-motor symptoms, with potential applications in other neurological disorders. The company targets several molecular mechanisms in astrocytes, a type of brain cell involved in maintaining neuronal function. It uses brain-penetrant compounds and translational drug discovery to develop disease-modifying treatments, rather than only symptomatic therapies.